In this study, we have shown that RANK gene expression increased after dual treatment with lapatinib and trastuzumab in HER2-positive tumor samples from the PAMELA clinical trial [22] and in HER2-positive breast cancer cell lines. Here, ERBB2 is linked to breast cancer.